A clinical phase-II trial of neoadjuvant chemoradiotherapy with S-1 and Gemcitabine for locally advanced pancreatic cancer (PerSeUS-GP02)
Phase 2
Recruiting
- Conditions
- ocally advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000010435
- Lead Sponsor
- PerSeUS: Perpetual Study estimated-by United Sections in gifu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Lung fibrosis or interstitial pneumonia. (should be confirmed by chest radiograph or CT within 28 days before the entry) 2. Watery diarrhea or chronic diarrhea 3. Regular use of Fenitoin, Warfarin or Frucitocin 4. Pleural effusion or ascites 5. Active infection 6. Other malignancies 7. Active gastroduodenal ulcer 8. Serious comorbid illness (heart failure, renal failure, liver failure, intestinal paralysis, uncontrolled diabetes, etc) 9. Serious mental disorder 10. Serious drug allergy 11. Pregnancy, breast feeding, or women who desire to preserve fecundity. Men who want his partner to be pregnant. 12. Patients who were judged inappropriate for the entry to this study by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-year survival rate
- Secondary Outcome Measures
Name Time Method Progression free survival Surgical resection rate Curative resection rate Response rate Safety